HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73834 | (Rac)-Arnebin 1 ((Rac)-β,β-Dimethylacrylalkannin; (Rac)-β,β-Dimethylacrylshikonin) | 5162-01-6 | (Rac)-Arnebin 1 ((Rac)-β,β-Dimethylacrylalkannin) is the racemate of β,β-Dimethylacrylalkannin and/or β,β-Dimethylacrylshikonin. |
|
V3952 | 1,4-DPCA | 331830-20-7 | 1,4-DPCA is a novel, potent and competitive inhibitor of prolyl 4-hydroxylase with IC50 value of 3.6 μM. |
|
V51644 | 1,4-DPCA ethyl ester | 86443-19-8 | 1,4-DPCA ethyl ester is the ethyl ester form of 1,4-DPCA and can inhibit FIH. |
|
V85084 | 5,3',4',3'',4'',5''-6-O-Ethyl-EGCG | 1613308-63-6 | |
|
V51627 | 7-Hydroxyneolamellarin A | 959662-26-1 | 7-Hydroxyneolamellarin A is a naturally occurring compound that can be found in the sponge Dendrilla nigra. |
|
V51637 | Acriflavine hydrochloride | 69235-50-3 | Acriflavine saltloride is a highly efficient fluorescent acridine dye that can be used for labeling. |
|
V10310 | Adaptaquin | 385786-48-1 | Adaptaquin is a novel and potent hydroxyquinoline inhibitor of HIF-PHD (hypoxia-inducible factor prolyl hydroxylase 2) with an IC50 of 2 μM. |
|
V86307 | AFP464 dihydrochloride (NSC710464 dihydrochloride) | ||
|
V1909 | Amifostine trihydrate (WR2721) | 112901-68-5 | Amifostine trihydrate (WR2721), a phosphorylated aminosulfhydryl compound, is the first approved radioprotective drug,it is used to decrease the risk of kidney problems caused by treatment with cisplatin. |
|
V51635 | Angiogenesis agent 1 | 2765218-28-6 | Angiogenic agent 1 (compound C-31) is a glycoside analog of a Rhodiola rosean analogue. |
|
V86107 | Arylsulfonamide 64B (HIF inhibitor 64B) | 1342890-83-8 | |
|
V78298 | Axl-IN-16 | Axl-IN-16 is a dual (bifunctional) inhibitor of Axl and HIF. | |
|
V32376 | Belzutifan (PT2977; MK-6482) | 1672668-24-4 | Belzutifan (PT-2977; MK-6482; PT2977; MK6482;Welireg)is a novel, selective and orally bioavailable HIF-2α (hypoxia-inducible factor 2α) inhibitor that has gained FDA approval in 2021 forthe treatment of von Hippel–Lindau disease-associated renal cell carcinoma. |
|
V5194 | Chlorogenic Acid (Heriguard; NSC-407296) | 327-97-9 | Chlorogenic acid (3-O-Caffeoylquinic acid; Heriguard; NSC-407296) is a naturally occuring phenolic compound found in coffee and tea. |
|
V2834 | Daprodustat (GSK1278863) | 960539-70-2 | Daprodustat (formerly known as GSK1278863; Duvroq) is a novel orally bioavailable hypoxia-inducible factor prolyl hydroxylase (HIF-PHI)inhibitor that has been approved for treatment of anemia associated with CKD/chronic kidney disease. |
|
V51630 | Dimethyl-bisphenol A | 1568-83-8 | Dimethyl-bisphenol A (DMBPA) is a potent HIF-1α inhibitor. |
|
V3443 | EL102 | 1233948-61-2 | EL102,a novel toluidine sulphonamide, is a novel inhibitor of HIF1α (hypoxia inducible factor) and can also potently inhibit tubulin polymerisation and decreased microtubule stability. |
|
V20522 | Enarodustat (JTZ951) | 1262132-81-9 | Enarodustat (formerly JTZ-951; JTZ951;Enaroy) is an orally bioactive hypoxia inducible factor-proly hydroxylase (HIF-PH) inhibitorapproved (in 2020) in Japan for the treatment of anemia associated with chronic kidney disease (CKD). |
|
V79383 | FAM-DEALA-Hyp-YIPMDDDFQLRSF-NH2 | FAM-DEALA-Hyp-YIPMDDDFQLRSF-NH2 is a 5-FAM-labeled HIF-1α peptide and a substrate of VHL. | |
|
V51626 | Fenbendazole-d3 | 1228182-47-5 | Fenbendazole-d3 is a cadmium-labeled fenbendazole. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
